Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis
Briefings in Functional Genomics · 2025
DOI: 10.1093/bfgp/elaf007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Briefings in Functional Genomics, 2025. Verfasst von Ruijie Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedical Informatics and Engineering, Kidney Disease Research Institute at the second affiliated hospital, Hainan Engineering Research C…. Hauptthemen laut MEDLINE: Neoplasms, Enhancer Elements, Genetic, RNA, Untranslated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hainan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Enhancer RNA (eRNA), a type of non-coding RNA transcribed from enhancer regions, serves as a class of critical regulatory elements in gene expression. In cancer biology, eRNAs exhibit profound roles in tumorigenesis, metastasis, and therapeutic response modulation. In this review, we outline eRNA identification methods utilizing enhancer region prediction, histone H3 lysine 4 monomethyl chromatin signatures, and nucleosome positioning analysis. We quantitate eRNA expression through RNA-seq, single-cell transcriptomics, and epigenomic integration approaches. Functionally, eRNAs regulate gene expression, protein function modulation, and chromatin modification. Key databases detailing eRNA annotations and interactions are highlighted. Furthermore, we analyze the connection of eRNA with immune cells and its potential in immunotherapy. Emerging evidence demonstrates eRNA's critical involvement in immune cell crosstalk and tumor microenvironment reprogramming. Notably, eRNA signatures show promise as predictive biomarkers for immunotherapy response and chemoresistance monitoring in multiple malignancies. This review underscores eRNA's transformative potential in precision oncology, advocating for integrated multiomics approaches to fully realize their clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biomedical Informatics and Engineering, Kidney Disease Research Institute at the second affiliated hospital, Hainan Engineering Research Center for Health Big Data, Hainan Medical University, 3 Xueyuan Rd, Lo…
Förderung
- Natural Science Foundation of Hainan Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, R., Chen, Z., Li, T., Feng, D., Liu, X., Wang, X., Han, H., Yu, L., Li, X., Li, B., Wang, L., & Li, J. (2025). Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis. Briefings in Functional Genomics. https://doi.org/10.1093/bfgp/elaf007
Vancouver
Zhang R, Chen Z, Li T, Feng D, Liu X, Wang X, et al. Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis. Briefings in Functional Genomics. 2025. doi:10.1093/bfgp/elaf007
BibTeX
@article{Zhang2025,
author = {Zhang, Ruijie and Chen, Zhengxin and Li, Tianyi and Feng, Dehua and Liu, Xinying and Wang, Xuefeng and Han, Huirui and Yu, Lei and Li, Xia and Li, Bing and Wang, Limei and Li, Jin},
title = {Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis},
journal = {Briefings in Functional Genomics},
year = {2025},
doi = {10.1093/bfgp/elaf007}
}
EUVIMED